|
Mar 6 Wed - MDG Boston FORUM
Life Saving Medical Imaging
and Diagnostic Innovations
|
- Ultrasonic echocardiography spots coronary artery plaques before they break and kill you
These advances in medical imaging
Mammography has dramatically reduced breast cancer mortality since becoming a recommended routine health screening. However, conventional 2D mammography missed many cancers in breasts with little radiolucent fat (dense breasts). It also required workups in women without disease.
3-D imaging in the human body, with CT and MRI, is a well-established method of medical imaging, but is expensive and produces a much higher radiation dose than the new 3D mammography (breast tomosynthesis) methods.
 Multiple clinical trials of 3D breast imaging demonstrated improved cancer detection, especially in denser breasts, while also reducing the false positive workups needed in women without disease. Andrew Smith, PhD, VP of R&D, Breast Health Division of Hologic, will discuss the science, technology, and clinical advantages of their 3-D breast imaging technology.
Increased use of catheter-based approaches in diagnosing and treating heart disease have increased demand for improved ultrasonic imaging techniques, such as locating the imaging device in the esophagus adjacent to the heart.
 Developed at Philips and tested at the Cardiovascular Division of Brigham and Women's Hospital in Boston, transesophageal and transthoracic echocardiography are compared clinically by Alexandra Goncalves, MD, PhD, Senior Medical Director, Cardiology Ultrasound, Philips Healthcare.
Boston Scientific is eliminating the operational inefficiencies and cost of reusable ureteroscopes, with LithoVue, a single-use digital flexible ureteroscope. LithoVue delivers detailed high resolution digital images for high quality visualization and navigation - to help urologists  remove stones quickly, easily, safely and affordably. Sarah Foley manages the Visualization R&D team in the Urology and Pelvic Health division at Boston Scientific developing new visualization techniques.
By detecting tiny pressure changes deep within tissues, ENDRA's Thermo Acoustic Enhanced Ultrasound (TAEUS)  will enable clinicians to visualize tissue composition, function and temperature in ways previously possible only on CT & MRI -- at 50X lower cost, at the point of care with existing ultrasound equipment, all without using ionizing radiation or contrast agents. ENDRA CEO Francois Michelon, took the company through a 2017 IPO and secured a strategic partnership with GE Healthcare.
|
Images provided courtesy of HOLOGIC, Inc. and affiliates
Wednesday
Regis College Fine Arts Center
Weston, MA
Early-bird Forum Fees (by Feb 27)
Member/Alliance Partner - $30
Non-member - $45
Student (member) - $10
Student (non-member) - $15
Gold Member - No Charge
Event Sponsorship - $500
(Contact Hank Allard for details -hallard@mdgboston.org)
Premier Annual Sponsors
 
Come join us for
an exciting evening
of science and hope!
|
- Engineers, Entrepreneurs, and Innovators who are filling the gaps in the unmet needs
of clinicians for medical diagnostics through imaging
- Managers and investors seeking opportunities in emerging medical imaging technology.
|
Our Distinguished Panel
|
|
|
|
 |
|
Sarah Foley, MS
Manager, Visualization R&D Team Urology and Pelvic
Health Division
Boston Scientific
|
Alexandra Goncalves, MD, PhD, MMSc, FESC
Senior Medical Director,
Cardiology Ultrasound
Philips Healthcare
|
Francois Michelon
CEO & Board Chair
ENDRA Life Sciences
|
Andrew Smith, PhD
Vice President of R&D BreastHealth Division Hologic
|
Jerry Shapiro, PhD MODERATOR
President and CEO
FEM-Medical,
Pres. Floelle, Inc.
MDG Boston BOD
|
Sarah Foley, MS
Manager, Visualization R&D Team Urology and Pelvic Health Division, Boston Scientific
Sarah Foley manages an R&D team in developing new visualization products to treat stone disease and co-leads a cross-functional franchise team that is responsible for the execution of the Visualization portfolio strategy. She has 10+ years of experience leading cross functional teams in design and development of leading edge products across the Aerospace, Energy and Medical Device industries. She worked on programs across the product lifecycle, from requirements development and system design to testing and verification.
Alexandra Goncalves, MD, PhD, MMSc, FESC
Senior Medical Director, Cardiology Ultrasound Philips Healthcare
Dr. Goncalves leads the evaluation of key medical trends for the Cardiology Business within the Ultrasound Business Group. She provides leadership and guidance on the design, implementation, monitoring and interpretation of clinical evaluations, including testing of new developments. In addition, she provides insights on the diagnostic potential of various clinical opportunities in the context of clinical and regulatory dynamics from a global perspective. She partners with clinical, scientific, regulatory and marketing leaders around the globe. Dr. Goncalves is a world-renowned expert in echocardiography. Her past experience includes research in epidemiology and new clinical applications for echocardiography in the Cardiovascular Department at Brigham & Women's Hospital / Harvard Medical School.
Francois Michelon, MBA
CEO & Board Chair at ENDRA Life Sciences
Mr. Michelon has 20 years of healthcare technology start-up, private-equity and Fortune 20 experience, spanning diagnostic imaging, surgical equipment, orthopedic and dental sectors. He has expertise in raising capital in the private and public markets, and building businesses across capital products, implantable devices and services. ENDRA's Thermo Acoustic Enhanced Ultrasound (TAEUS) will enable clinicians to visualize tissue composition, function and temperature in ways previously possible only on CT & MRI -- at 50X lower cost, at the point of care. ENDRA's first clinical application targets early detection of Non-Alcoholic Fatty Liver Disease (NAFLD), affecting over 1 billion people globally.
Andrew Smith, PhD
Vice President of R&D Breast Health Division of Hologic
Andy Smith has been involved in medical imaging research and development for over 30 years, with a current focus on advanced breast imaging technologies such as tomosynthesis. He lectures widely around the world on breast imaging and physics, and is a co-author on over 50 patents and patent applications. Prior to Hologic he was VP and a co-founder of Digital Scintigraphics, a company that developed and sold high resolution nuclear medicine neuroimaging systems. He received his BS and PhD degrees in physics from MIT.
Jerry Shapiro, PhD MODERATOR
President and CEO FEM-Medical, Pres. Floelle, Inc. MDG Boston Board Member
Dr. Shapiro was the first person at Boston University with an earned doctorate in Bioengineering, cofounder of their Department of Biomedical Engineering, Principal Investigator on many NIH grants, Director of two laboratories in glaucoma and ocular physiology and held the positions of Research Scientist, and Associate Professor of Surgery, Medicine, Ophthalmology and Biomedical Engineering.
Co-Champions
|
Jerry Shapiro, PhD
President & CEO FEM-Medical,
President, Floelle, Inc.
MDG Boston Board Member
|
 |
Andrea Cahill
Electrical Engineer
Boston Scientific
MDG Boston Board Member |
|
Fees - (Light dinner included)
| Fee Category |
Early Registration
|
Week Prior
|
At the Door
|
| Member/Alliance Partner: |
$30 |
$35 |
$45 |
| Non-Member: |
$45 |
$55 |
$65 |
| Student Member |
$10 |
$12 |
$15 |
| Student Non-member w/ a valid ID |
$15 |
$18 |
$20 |
| Gold Member |
No Charge |
No Charge |
No Charge |
Event Sponsor - $500 - (Contact Hank Allard for details - hallard@mdgboston.org)
About MDG
The premier MedTech community advancing healthcare
by enabling diverse professionals to grow through
expert forums, collaboration, and knowledge sharing.
The Medical Development Group (MDG) is a community of individuals professionally committed to the Medical Device and other Medical Technology Industry segments united by the belief that innovation and advances in technology lead to substantial improvements in health care. MDG pursues this mission through the organization of educational programs and forums: the facilitation of cross-disciplinary dialogue and collaboration; the creation of venues for networking and information sharing for current and aspiring professionals, clinicians, and entrepreneurs; and the development of alliances with complementary organizations.
|
|
|
Print Page
ILSA 
